SONTRA MEDICAL SERVES PATENT INFRINGEMENT NOTICE FOR DERMISONICS' TRANSDERMAL INSULIN DELIVERY SYSTEM

Sontra Medical Corporation announced today that it has sent a notice to Dermisonics, Inc. stating Sontra's belief that, upon commercialization, Dermisonics' U-Strip ultrasonic transdermal delivery system for insulin and other drugs will infringe one or more of Sontra's patents. On February 1, 2006, Sontra sent a letter to Dermisonics stating that Sontra believes that the U-Strip system currently infringes, or will infringe, the claims in Sontra's U.S. patent numbers 6,002,961, 6,190,315, and/or 6,491,657, noting that the penalties for such infringement are severe, including a preliminary and permanent injunction, treble damages and attorneys' fees.
PR Newswire